Prestigious Journal Publishes Case Study Highlighting T-19.

Business Editors & Health/Medical Writers

HONOLULU--(BW HealthWire)--April 4, 2002

T-19 Incorporation (which has entered into a letter of intent to be acquired by LCS Golf) (OTCBB:LCSG) announced today that the International Journal of Dermatology has published a case study detailing the use of Tubercin.

The International Journal of Dermatology, published by Blackwell Science, Ltd. of London, England, (Vol 41:1 paper 1388) printed the case study written by Tubercin inventor, Dr. Tai-Ho Chung in its January 2002 edition. The article is entitled, `Regression of an acral lentiginous melanoma with an immunotherapy using a Mycobacterium tuberculosis-extracted polysaccharide complex (Tubercin).'

The case study documented the successful treatment of Acral Lentiginous Melanoma on a 77-year-old woman with Tubercin. The woman was diagnosed with terminal Acral Lentiginous Melanoma on her arm and was given three to four months to live if the arm was not amputated. The woman refused amputation and sought out Dr. Chung to administer Tubercin and began her treatment on December 24, 1999. On December 28, 2000 an official biopsy was performed and the woman was declared cancer free. The entire article can be reviewed at: http://www.tubercin.com.

LCS Golf President Michael Mithcell, M.D. stated, "The publication of this case study in a well known and well respected medical journal is obviously very good news. The successful treatment outlined in the article will help increase the credibility of the product and will likely create additional demand for the T-19 nasal spray."

Earlier this week, LCS Golf announced that the Pickens Group and its CEO, Michael O. Pickens had purchased 2,000,000 shares of LCSG stock for $1,000,000. The proceeds from this equity investment will be used to complete the acquisition of T-19 Incorporation.

Disclaimer: Statements, which are not historical facts, are forward-looking statements. The Company, through its management, makes forward-looking public statements concerning its expected future operations, performance and other developments. Such forward-looking statements are necessarily estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements.